Results 51 to 60 of about 5,356 (175)
European Journal of Neurology, Volume 33, Issue 8, August 2026.This first nationwide study of motor neuron diseases (MNDs) in Latvia provides epidemiological and clinical data about 181 patients identified with motor neuron diseases during a 5‐year observational period revealing lower incidence and prevalence rates compared to other European countries.
Vladimirs Krutovs +9 more
wiley +1 more source
Brazilian Journal of Medical and Biological Research, 2014 Studies have shown that edaravone may prevent liver injury. This study aimed to investigate the effects of edaravone on the liver injury induced by D-galactosamine (GalN) and lipopolysaccharide (LPS) in female BALB/c mice.
L. Zong, Q.H. Yu, Y.X. Du, X.M. Deng
doaj +1 more source
ChemMedChem, Volume 21, Issue 14, 29 July 2026.Following the discovery of oxadiazin‐5‐ones as partial inhibitors of the ATP synthase, we herein report the synthesis of a library of pyrazolidine‐3‐ones and pyrazol‐3‐ones, designed by reducing the six‐membered N–N heterocycles to five‐membered rings.
Lisa Reichert +8 more
wiley +1 more source
Evaluation of edaravone against radiation-induced oral mucositis in mice
Journal of Pharmacological Sciences, 2015 Oral mucositis induced by radiotherapy for cancers of the head and neck reduce the quality of life of patients. However, effective therapeutic agents are lacking. Symptomatic treatment involves local anesthesia and analgesia.
Noriko Nakajima +5 more
doaj +1 more source
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. [PDF]
PLoS ONE, 2014 Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models.
Yu-Yo Sun +9 more
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.The novel PAD4 inhibitor YJ‐2 potently suppresses neutrophil extracellular trap (NETs) formation. In a rat model of ischemic stroke, YJ‐2 treatment significantly reduces cerebral infarct volume and improves neurological function, demonstrating its therapeutic potential.
Yijiang Jia +8 more
wiley +1 more source
Basic and Clinical Neuroscience, 2019 Introduction: Parkinson disease (PD) is the second most common neurodegenerative disease affecting older individuals with signs of motor disability and cognitive impairment. Epicatechin (EC) and edaravone have neuroprotective effects most probably due to
Mohammad Shokrzadeh +6 more
doaj
Microglial Mitochondrial Dysfunction: The Storm Center of Post‐Stroke Neuroinflammation
CNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.Stroke disrupts microglial mitochondrial homeostasis, leading to acute damage and metabolic dysfunction that amplify pro‐inflammatory signaling. Although quality control mechanisms initiate protective responses, persistent stress overwhelms them. The resulting imbalance drives a self‐reinforcing neuroinflammatory storm that exacerbates secondary brain ...
Ruchong Fan +8 more
wiley +1 more source
Interdisciplinary Medicine, Volume 4, Issue 4, July 2026.Hydrogel‐based drug delivery systems offer a promising approach for treating intracerebral hemorrhage (ICH) by overcoming blood‐brain barrier limitations, enabling precise, sustained release of neuroprotective and anti‐inflammatory agents. These systems enhance treatment efficacy, but challenges remain in biosafety, drug penetration, and scalability ...
Haojun Shi +18 more
wiley +1 more source
Proteolytic remodelling of the extracellular matrix by pericytes
The FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard +4 more
wiley +1 more source